Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients

4 Nov 2010

Abstract excerpt

BACKGROUND: The spike (S) protein of SARS-CoV not only mediates receptor-binding but also induces neutralizing antibodies. We previously identified the receptor-binding domain (RBD) of S protein as a major target of neutralizing antibodies in animal models and thus proposed a RBD-based vaccine. However, the antigenicity and immunogenicity of RBD in humans need to be characterized. RESULTS: Two panels of serum...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21047436
DOI: 10.1186/1743-422x-7-299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patientsPMID 21047436Read ↗

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsSemantic proximity Read ↗

The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesSemantic proximity Read ↗

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunitySemantic proximity Read ↗

Receptor-binding domain as a target for developing SARS vaccines.Semantic proximity Read ↗

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccineSemantic proximity Read ↗

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal modelSemantic proximity Read ↗

Antibodies and Vaccines Target RBD of SARS-CoV-2Semantic proximity Read ↗

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and VaccinesSemantic proximity Read ↗

B-Cell Responses in Patients Who Have Recovered from Severe Acute Respiratory Syndrome Target a Dominant Site in the S2 Domain of the Surface Spike GlycoproteinSemantic proximity Read ↗

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic AntibodiesSemantic proximity Read ↗

Immunological Characterization of the Spike Protein of the Severe Acute Respiratory Syndrome CoronavirusSemantic proximity Read ↗

Rapid generation of neutralizing antibody responses in COVID-19 patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.